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Abstract: Correct measurement of autoantibodies is 
essential for the diagnosis of autoimmune diseases. How-
ever, due to the variability of autoantibody results and the 
heterogeneity of testing, wrong diagnosis is a reality. For 
this and more reasons, harmonization of testing is of the 
outmost importance. In this review we have summarized 
the factors contributing to this variability. The ways with 
which the working group on harmonization of autoanti-
body testing of the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) has been try-
ing to tackle the issue with the production and correct 
use of certified reference materials (CRMs), is discussed. 
Finally the advantages and the limitations of the use of 
CRMs are presented.
Keywords: autoimmune disease; certified reference mate-
rials; harmonization; standardization.
Autoimmune disease
The term autoimmune diseases covers a rather wide range 
of diseases in which body tissues are damaged or dysfunc-
tion due to an abnormal immune response to self-anti-
gens [1]. The classification of a disease as an autoimmune 
depends on a number of criteria, such as the target antigen 
and the presence of T-cells and/or antibodies in a target 
organ or the loss of B-cell tolerance [2–4]. Autoimmune 
diseases are thought to occur in genetically susceptible 
individuals after they have been exposed to environmen-
tal factors [5]. Independently of the underlying cause, the 
impact of having an autoimmune disease on the patient, 
their families and wider society can be immense [6].
There are more than 100 diseases currently charac-
terized as autoimmune [6] and they are part of a spec-
trum from one affected organ (organ-specific) to systemic 
conditions. In many autoimmune diseases, antibodies 
against one specific antigen are involved, however, in 
some autoimmune diseases antibodies to several antigens 
may be involved. Autoimmune diseases such as rheuma-
toid arthritis and type 1 diabetes are well recognized but 
there are many rare autoimmune diseases such as juvenile 
dermatomyositis or myasthenia gravis. Taken together 
autoimmune diseases affect many people, and can have 
a major impact on a patient’s wellbeing. Using prevalence 
data for 29 autoimmune diseases Cooper et  al. [7] esti-
mated that the global prevalence of autoimmune disease 
is between 7.6 and 9.4%.
The healthcare costs burdening governments around 
the globe for the treatment and follow-up of patients 
with an autoimmune disease is enormous. According to 
a report published in 2011 by the American Autoimmune 
Related Diseases Association (AARDA) and the National 
Coalition of Autoimmune Patient Groups (NCAPG) [8] 
more than $100 billion are spent yearly for their treatment 
in the United States.
Laboratory measurement 
of autoantibodies
The detection and quantification of disease associated 
autoantibodies is central to the diagnosis, treatment and 
monitoring of many autoimmune diseases. Early diagno-
sis and treatment improves the likelihood of remission 
in the majority of autoimmune diseases and reduces the 
possibility of permanent tissue damage [9]. The reliability 
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of autoantibody measurements is therefore crucial for 
optimum patient care.
Historically, manual, qualitative or semi-quantitative 
indirect immunofluorescence assays have been used for 
the detection or screening of autoantibodies. ELISA-based 
assays have been used as follow-up investigations to 
confirm and quantify the concentration of an autoanti-
body in blood serum. These measurements have tradition-
ally been performed in specialized sections of pathology, 
e.g. immunology laboratories. However, autoantibody 
testing is now commonplace with an increasing tendency 
towards more automated methods providing numeri-
cal results with faster throughput. Currently, there are at 
least three fully automated platforms in the market for the 
detection of antibodies associated with systemic small 
vessel vasculitis.
A laboratory result must be of value to the requesting 
clinician who will in turn need appropriate information to 
interpret it. The specificity (negativity in health) and sen-
sitivity (positivity in disease) of the test(s) must be consid-
ered to ensure that they are capable of contributing to the 
diagnosis, prognosis or monitoring of patients. The result 
will need to be related to a reference range or a cut-off 
value appropriate to the test and to the patient being 
investigated [10]. Increasingly, tests and their results are 
incorporated into protocols or best practice guidelines. To 
fulfill these requirements, a laboratory test should give a 
consistent result wherever it is measured and by which 
ever method.
Variability of autoantibody 
 measurement results
As the number of available techniques for the measure-
ment of autoantibodies is increasing, so is the concern 
with regard to the comparability of the obtained results. 
The detection and quantification of autoantibodies are 
fraught with problems. Laboratories around the world are 
required to participate in external quality assurance (EQA) 
schemes. It has been shown in various EQA studies [11] 
that both the within- and the between-method variation 
is very large even when the same units are used. The chal-
lenges of result comparability highlighted by EQA schemes 
have been summarized by Meroni et  al. [12] in a review 
article published in Nature Reviews. Different laboratories 
using the same method may produce results varying up 
to a factor of 100. Additionally, different methods using 
the same units have been shown to in fact use scales 
that differ considerably, by up to a factor of 5 (e.g. for IgG 
myeloperoxidase anti-neutrophil cytoplasmic autoanti-
bodies [MPO ANCA] [13]). The problems are however not 
only numerical, but also qualitative. For MPO ANCA IgG it 
was shown that out of 30 routine samples only 10 samples 
had the same qualitative interpretation when tested in 11 
different assays [13].
Factors contributing to the variability 
of autoantibody results
 – The growing number of in vitro diagnostics (IVD) 
methods with a wide variety of formats, reagents and 
signal detection systems may lead to de facto different 
method selectivities, even if they intend to measure 
the same analyte.
 – Many methods, particularly the manual ELISAs have 
high coefficient of variability (CV) for repeatabil-
ity and intermediate precision. Because of this, the 
uncertainty on a single measurement is high.
 – Measurement scales used by the different meth-
ods for the same analyte can vary up to a factor of 
100. In addition, antibody concentrations are often 
expressed in the same arbitrary units (e.g. “units” 
or “IU”), which further increases the confusion. In 
principle this does not prevent the proper use of the 
results, provided the scales are stable over time, and 
that the right cut-offs are used. However, it is clear 
that different classifications of patients are obtained 
even if the corresponding cut-offs provided by the 
manufacturers are used [13].
 – In some cases different methods are using the same 
units (e.g. “units” or “IU”) but in reality employ very 
different scales, which can lead to confusion. A con-
sensus discussion on how to deal with different units 
and scales could improve this issue.
 – Differences in test specificity and test efficiency can 
be seen, even in the presence of reliable standards. 
These differences may be between batches from one 
individual manufacturer or between kits from differ-
ent manufacturers. These underlying causes are likely 
to be multi-factorial and include variability in the cali-
brators, enzyme substrates, antigens and antibodies 
between the different kits.
 – The calibration of autoimmune measurements is not 
always optimal. The translation from the method sig-
nal (e.g. optical densities [ODs]) to method units is 
typically via a calibration curve. The calibration curve 
is usually non-linear with a sigmoid curve, at least for 
ELISAs. The method optimization is vital and should 
Unauthenticated
Download Date | 6/14/18 1:12 PM
Monogioudi et al.: Standardization of autoimmune testing      3
focus on generating the most reliable concentration 
values at clinically critical values. However, the num-
ber of calibration points may be very low and cover a 
large concentration range. Any variation in any stand-
ard can skew the standard curve sufficiently to alter 
the interpretation of borderline results. The flattened 
curve seen at low and high concentrations can give 
high analytical imprecision both within and between 
batches and can therefore make monitoring patients 
difficult. This has been noted for MPO ANCA IgG anal-
ysis by Hutu et al. [13] where the coefficient of varia-
tion (CVs) for reported results in method units were 
much larger than seen for the raw OD values.
 – The antibodies made by each individual patient are 
likely to be slightly different from those made by other 
patients; they may differ in class, subclass but most 
importantly in selectivity, affinity and avidity for the 
antigen. Methods that describe measuring the same 
analyte may actually be detecting only certain small 
parts of the three-dimensional antigen molecule. 
These factors contribute to the poor correlation that 
may be seen between methods. For example, one 
sample may give a high value in method A and a low 
value in method B, whereas a sample from a differ-
ent patient will give a low value in method A and a 
high value in method B. Furthermore the reactivity of 
autoantibodies can change within a patient from the 
time of diagnosis, through treatment and into remis-
sion. Some methods may show good correlation with 
other usually similar methods but for other combi-
nations of methods the scatter may be severe. It is 
important to remember that poor correlation between 
methods that is due to sample characteristics’ and 
the differences in selectivities between the methods 
will not be improved by the introduction of a common 
reference material (RM). Laboratories should have a 
robust procedure to validate their assays when first 
adopted and for continual monitoring of the testing. 
Internal quality control (IQC) and EQA procedures are 
fundamental to these processes.
Standardization, harmonization 
and certified reference materials
According to the ISO/IEC Guide 2:2004, standardization 
is the “activity of establishing, with regard to actual or 
potential problems, provisions for common and repeated 
use, aimed at the achievement of the optimum degree of 
order in a given context” [14].
The Clinical and Laboratory Standards Institute 
refers to a definition of “(method) harmonization” as “the 
process of recognizing, understanding, and explaining 
differences while taking steps to achieve uniformity of 
results, or at a minimum, a means of conversion of results 
such that different groups can use the data obtained from 
assays interchangeably” [15]. In terms of measurement 
results in clinical chemistry the focus of standardization 
is the term “repeated use”. Standardization implies long-
term comparability of measurement results, preferably 
through traceability of measurement results to a stable 
reference. On the other hand, the focus of the term harmo-
nization is on uniformity of results.
Standardization through the proper implementation 
of a reference system should ideally support the equiva-
lence of measurement results over different procedures, 
laboratories and over time. However, equivalence of 
measurement results also depends to a large extent on 
all the other factors contributing to variability, like the 
repeatability of methods and sample-specific differences. 
It cannot be achieved by traceability to a reference system 
alone.
A reference system should provide traceability to a 
stable reference, such as an RM or a reference method. 
An RM is a material, sufficiently homogeneous and stable 
with respect to one or more specified properties, which has 
been established to be fit for its intended use in a meas-
urement process. A certified reference material (CRM) is 
characterized by a metrologically valid procedure for one 
or more specified properties, accompanied by a certifi-
cate that provides the value of the specified property, its 
associated uncertainty, and a statement of metrological 
traceability. A CRM thus provides a measurement scale, 
whether arbitrary or SI derived values are being used. The 
use of CRMs has as a major advantage the fact that repro-
ducibility over longer times can be possible as long as the 
procedures followed by individual manufacturers are well 
controlled. These procedures would cover all aspects from 
the reconstitution of the CRM, to the preparation of dilu-
tions and the use of valid protocols for the value transfer 
to intermediate calibrators.
The quantification of autoimmune biomarkers pre-
sents particular challenges because of the nature of the 
entity measured. The analyte is an antibody against a 
named antigen and, immunoassays rely on detecting the 
binding of the analyte to its natural antigen. The antigens 
associated with an autoimmune disease are typically large 
proteins with multiple epitopes but the lack of knowledge 
regarding an antigen’s epitopes with respect to its analyti-
cal reactivity but also clinical importance is a significant 
issue that is hard to address. Consequently, autoantibodies 
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with different epitope specificities will often produce 
discrepant results depending on the method selectivity. 
Where evidence regarding clinically relevant epitopes is 
available, assay manufacturers should produce appro-
priate assays. Difference between the affinities of the 
antibodies in the patients samples and of the calibrator 
will have an impact on the accuracy of the assay [16]. It is 
desirable that calibration material has a comparable affin-
ity to that of the typical patient sample. A common stand-
ard or RM must resemble routine samples with respect to 
the most relevant influence parameters ensuring commut-
ability among different measurement procedures [12]. It is 
important to stress that the main requirement for an RM 
that is fit for purpose, is its commutability, i.e. the fact 
that it behaves in the same way as a patient sample with 
respect to the relevant methods.
According to the EU Directive on In Vitro Diagnostic 
Medical Devices (IVD-MD) (Directive 98/79/EC), any mate-
rial intended to serve as a calibrant or as a control material, 
must be traceable to reference measurement procedures 
and/or RMs of higher order, if they are available.
IFCC WG-HAT
It is well established that the detection and quantifica-
tion of IgG antibodies to autoantigens are important for 
the diagnosis and monitoring of a number of autoimmune 
diseases. In 2009 the International Federation of Clini-
cal Chemistry and Laboratory Medicine (IFCC) formed a 
new working group with a mandate for the Harmoniza-
tion of Autoantibody Tests (known as WG-HAT). The Joint 
Research Centre of the European Commission is partici-
pating in this working group and is responsible for the 
development and production of CRMs based on a series 
of agreed targets. These initial targets for the standardiza-
tion of autoantibody measurement results are set accord-
ing to their acute, well-defined clinical use.
The targets and their selection
The expert group forming the WG compiled a list of 
autoantibodies where the concentration of the antibody 
was important for diagnosis and more importantly, for 
disease or treatment monitoring and where harmoniza-
tion of results could reduce clinical risk.
These are IgG autoantibodies to:
 – Double stranded DNA – one of the classification cri-
teria for systemic lupus erythematosus (SLE) and 
used for monitoring disease activity and response to 
 treatment [17–19].
 – Glomerular basement membrane – a pathogenic anti-
body that mediates anti-GBM disease. It is typically of 
an IgG type even though IgA and IgM types can also 
been present. The diagnosis and prognosis depends 
on early detection of the antibody [20–22] and during 
treatment, the concentration of the antibody is used 
to monitor disease activity and response to therapy.
 – Anti-cardiolipin and anti-beta 2 glycoprotein 1 anti-
bodies – antibodies associated with a higher risk 
of thrombosis in veins and/or arteries and preg-
nancy complications. Their presence is indicative for 
antiphospholipid syndrome (APS) [23–26].
 – Proteinase 3 – one of the targets for anti-neutrophil 
cytoplasmic antibodies (ANCA) that is strongly 
implicated in the pathogenesis of ANCA small ves-
sel associated vasculitis. PR3 ANCA IgG are found 
in about 80% of patients with granulomatosis with 
polyangiitis (GPA), and in about 35% of patients with 
microscopic polyangiitis (MPA), eosinophilic granu-
lomatosis with polyangiitis (EGPA), and renal-limited 
rapidly progressive glomerulonephritis [27, 28]. Detec-
tion and quantification of PR3 ANCA IgG is important 
for diagnosis but also for monitoring disease activity 
and response to therapy.
 – Myeloperoxidase – another target of ANCA, impli-
cated in the pathogenesis of ANCA small vessel asso-
ciated vasculitis, especially of patients suffering from 
MPA and EGPA. Detection and quantification of MPO 
ANCA IgG is similarly important.
 – Anti-citrullinated protein antibodies (ACPA) – anti-
bodies that are present in patients with rheumatoid 
arthritis and are therefore used as markers for diag-
nosis of the disease [29] but are also used alongside 
other markers for risk stratification and as prognostic 
indicators.
The IFCC working group (WG-HAT) addressed a number of 
questions regarding these targets.
Are there different methods 
measuring the same analyte – 
do the methods provide correlating 
results?
Prior to starting any standardization initiative, it is impor-
tant to evaluate the consistency of the entities measured 
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by the different methods to be standardized. The numeri-
cal values may show marked variation but methods claim-
ing to detect the same analyte should produce results that 
show a consistent relationship [30].
Practically, this can be done by analyzing a set of 
routine clinical samples covering the whole analytical 
range using all the methods available. The data can be 
plotted in a method A vs. method B graph providing a 
visual estimate of the correlation and linearity and statis-
tical analysis will provide numerical values for these char-
acteristics. Poor correlation between methods is a serious 
impediment for standardization and the underlying 
causes need thorough evaluation. If there is no consist-
ent relationship in values between methods, recalibration 
alone will not be sufficient to achieve comparable results 
on the level of individual samples.
Data from EQA schemes show the marked variation 
in autoantibody results from different methods and this 
is supported in the scientific literature. Anti-cardiolipin 
antibodies (aCL) is an important test for the diagnosis of 
anti-phospholipid syndrome (APS) but there is a number 
of studies [31–35] showing the lack of agreement between 
the methods used for the analysis. These reasons vary 
from the preparation or formulation of the antigen, to the 
method characteristic and these lead to differences in the 
cut-off values and therefore to the final interpretation of 
the results. Kutteh and Franklin distributed samples from 
20 patients to 10 different centers for measurement of 
antibodies to cardiolipin and other phospholipids. They 
showed that results from different centers were in agree-
ment in only 45% of the cases [36]. Many studies suggest 
that, patient samples should be tested by more than one 
method whenever possible whether a common standard 
is used or not [36].
A similar situation has been described for MPO and 
PR3 ANCA by Bossuyt et al. [37], who found a lack of corre-
lation between different methods for PR3 and MPO ANCA 
although the correlation was better between methods 
using a similar analytical process. Hutu et al. [13] showed 
a fairly good correlation for patient samples between 
most methods (Figure  1) although results from different 
methods (in terms of positive or negative) could be dif-
ferent. It was shown that recalibration and the use of a 
common cut-off could considerably reduce the variation 
of results although certain methods did not give compa-
rable results, presumably due to different analytical selec-
tivity. This finding does not mean that these methods are 
not valid, but it does suggest that they may be detecting 
antibodies in a different sub-set of patients. These find-
ings also highlight the importance of a better understand-
ing of the root cause of variation in autoantibody testing.
Is it possible to produce 
a commutable reference material 
for autoantibody tests?
The selection of a raw material and the stabilization of 
a raw material are crucial steps in the production of an 
RM. There are different options for starting materials. 
These include plasmapheresis materials, pooled plasma 
or serum samples, and the use of monoclonal antibodies, 
eventually spiked into a serum-like background. It may 
seem that any matrix-matched (serum) material should 
be suitable. This is an assumption that has also been 
made for RMs for other analytes, and has been shown not 
always to be valid. There are different reasons why real 
serum material from patients could still be unsuitable for 
producing an RM:
 – The raw material could contain antibodies that are 
outliers in their analytical behavior, with respect to 
antibodies in the majority of patient samples. For 
example, in Figure  2 the plasmapheresis materials 
shown as a filled triangle or a filled large square show 
a bias of about 30% with respect to the regression line 
of the patient samples. If this plasmapheresis mate-
rial would be used for calibration of the two meth-
ods it would result in an average bias of 30% for the 
patient samples.
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Figure 1: Examples of good (above) and poor (below) correlation 
between measurement results from three methods that target MPO 
ANCA IgG antibodies.
Unauthenticated
Download Date | 6/14/18 1:12 PM
6      Monogioudi et al.: Standardization of autoimmune testing
 – The material could have stability problems, changing 
in properties over time.
 – Processing of the material, like freeze-drying, can 
change the oligomeric state of antibodies, or lead to 
lack of between-vial homogeneity.
The ability of an RM to perform comparably to tested 
routine samples is called commutability and it is one of 
its most important characteristics [38]. Reference prepara-
tions made from serum in its close to native state may have 
issues with the complexity of the constituent proteins and 
even protein interactions that may all generate interfer-
ences and poor commutability. Reference preparations 
made from purified proteins may show a lack of commut-
ability because of degradation or structural modifications 
made to the proteins during isolation and purification, 
or because of a different matrix composition. There are 
also advantages and disadvantages to using samples from 
one patient, e.g. with plasmapheresis fluids or to using 
mixtures of a large number of donations from individual 
patients. There is no a priori rationale for choosing the 
one or the other strategy for the selection of raw material 
and processing conditions. Instead the selected material, 
or preferably different candidate materials, should be 
tested for commutability.
Despite the challenges, finding a material that is 
commutable is not impossible. Hutu et al. [13] completed 
a study for myeloperoxidase MPO ANCA IgG, where 18 
forms of candidate materials were analyzed with differ-
ent manufacturer assays. The results for both patient 
samples and candidate RMs were plotted in pairs. It was 
shown that results correlated reasonably well for a subset 
of the methods, while for other combinations there was 
little correlation (Figure 3). The group continued with a 
second commutability study, where the five best forms 
of the candidate material were analyzed using 11 assays 
(manual ELISAs, a multiplex based assay, a fluores-
cence assay and a chemiluminescent assay). That study 
resulted in the selection of a freeze-dried form that was 
finally chosen by the group as the material to be devel-
oped and certified [13].
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Figure 2: Correlation between optical density (OD) responses for 
two PR3 ANCA IgG methods.
Results for routine patient samples are shown as small squares, 
candidate reference materials as larger symbols.
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Figure 3: Example of good (above) and poor (below) correlation 
between measurement results from three methods that target MPO 
ANCA IgG antibodies for both patient samples (PS) and various 
candidate reference materials (SSIB is a random code given for a PS) 
these samples were processed and diluted whether in human serum 
or in human serum albumin.
Purified PR3 ANCA IgG was spiked into filtered unprocessed serum.
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Figure 4: Correlation between optical density (OD) responses (x) and 
concentration estimates (rhombus) of two PR3 ANCA IgG methods.
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PR3 ANCA IgG candidate RMs have also been evalu-
ated in feasibility studies comprising methods from 
several manufacturers. Some serum materials were com-
mutable for all but one method that where compared 
with respect to their assay response (i.e. optical density). 
Interestingly, correlation between methods significantly 
worsened when considering the calculated PR3 ANCA IgG 
titers (Figure 4), which points at potential calibration defi-
ciencies. In case these issues would be related to the use 
of non-commutable calibrators, a common suitable RM 
could improve methods’ comparability. It is important to 
remember that the preparation of an RM is only the first 
step; other areas that must be robust include the value 
transfer to intermediate calibrators, selecting the appro-
priate curve fitting model and ensuring linearity over a 
clinically useful concentration range.
Can values be assigned in a manner 
that they are traceable to a stable 
reference?
A pivotal requirement for a calibrator according to ISO/
IEC 17511 is the metrological traceability of the material 
[39]. It is defined as the “property of a measurement result 
whereby the result can be related to a reference through 
a documented unbroken chain of calibrations, each con-
tributing to the measurement uncertainty”. The mass 
concentration values assigned to CRMs for MPO and PR3 
ANCA (ERM-DA476/IFCC and ERM-DA483/IFCC, respec-
tively), are operationally defined by the immunoassay 
procedures used to characterize them and are traceable 
to the stated value of the mass concentration of total IgG 
in United States National Reference Preparation (USNRP) 
12-0575C [40]. The certification report accompanying the 
release of any CRM will contain a graphical presentation 
and detailed explanation of the traceability chain [41].
The RMs for both MPO ANCA and PR3 ANCA enable 
consistent results to be generated using a large number of 
methods. However, some methods show outliers in both 
concentration and clinical interpretation. It is likely that 
the relative success of these materials originates in the 
initial selection of the raw material, which was chosen 
because it behaved as an “average” patient sample within 
the evaluation methods. However, as previously dis-
cussed, the properties of IgG ANCA in individual patient 
samples can be variable so we are aware that some patient 
samples and in some methods will be impossible to cali-
brate using the existing RM.
Progress in the development 
of CRMs
A number of CRMs has been developed, certified and 
released by the JRC in collaboration with the IFCC for 
standardization of the mass concentrations of various 
proteins. These include ERM-DA470k/IFCC for 12 human 
serum proteins including total IgG, ERM-DA471/IFCC for 
cystatin C and ERM-DA474/IFCC for C-reactive protein. 
More recently and as briefly mentioned above, the JRC 
released two serum protein materials for the standardi-
zation of measurements of PR3 ANCA IgG (ERM-DA483/
IFCC) [41] and for the measurement of MPO ANCA IgG 
(ERM-DA476/IFCC) [42]. These materials represent a sig-
nificant step forward in the harmonization of autoanti-
body tests as the first CRMs with values assigned in mass 
units for a specific IgG antibody. The production of these 
materials has taken approximately 6 years but in addition 
to producing and certifying them, we have gained consid-
erable experience in the area of autoantibody standardi-
zation which should enable the development of further 
materials using the same well-defined protocols.
Preparation of a CRM certified for the mass concentra-
tion of β-2-glycoprotein I antibodies in human serum that 
are associated with occurrence of arterial and/or venous 
thrombosis as well as with recurrent miscarriage [43] is 
in progress. The IFCC committee on harmonization of 
autoantibody testing and the JRC are planning the produc-
tion of a certified reference preparation for IgG antibodies 
to the glomerular basement membrane and considering 
producing an RM for IgG and IgA anti-tissue transglutami-
nase antibodies. Other groups have expressed their inten-
tion to prepare RMs for IgG anti-double stranded DNA, 
anti-cyclic citrullinated peptide and rheumatoid factor.
Advantages and limitations of the 
use of certified reference materials 
for testing for autoimmune 
antibodies
Tests for autoantibodies are important in the diagnosis 
and monitoring of autoimmune disease with many tests 
forming part of the diagnostic criteria. Many methods for 
autoimmune antibodies show good clinical significance 
but there are still important issues with limited RMs and 
high variability between methods, making robust result 
interpretation difficult.
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An RM can provide an anchor point for working on 
those issues. They can be used for quality control, to 
detect and reduce within and between-laboratory vari-
ation. When methods provide correlating results they 
can be used to put these methods on the same scale, 
provided that they are commutable. Importantly, they 
can also be used by IVD manufacturers to keep scales 
stable over time. They will however not solve all issues, 
and will not reduce variability between non-correlating 
methods. Some methods will certainly generate different 
numbers and different interpretations for some samples 
but provided the laboratory is consistent in the method 
used for their patients, and the clinicians are aware 
that results for the same test name are not necessarily 
comparable, clinical risk should be limited. A better 
understanding of the underlying causes of variability in 
autoantibody testing should enable us to find ways to 
inform our users; this may involve more detailed nomen-
clature of the tests, e.g. PR3 ANCA capture method or 
PR3 ANCA direct ELISA. It may also lead to better defini-
tion of the antigens involved in the testing, e.g. defining 
the epitopes that are reactive in a particular assay. We 
are aware that true harmonization or standardization 
of autoantibody testing may be a multi-step process but 
having one stable “point of reference” in an analytical 
system is the vital first step in improving the quantifica-
tion of autoantibody testing.
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